Ben Gruenstein Speaks at ECI’s 2023 Fellows Meeting
July 18, 2023
On July 13, 2023, Cravath partner Benjamin Gruenstein participated in the Ethics & Compliance Initiative’s 2023 Fellows Meeting, which was held from July 12‑14, 2023 in Washington, D.C. and convened leading practitioners and academics to discuss the role of ethics and compliance in the landscape of evolving responsibilities for companies. Ben spoke on a panel entitled “Transforming Corporate Governance to Meet a New World,” which addressed how companies can address global challenges through effective board governance.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 1999, Harvard Law Schoolmagna cum laude
-
A.B., 1996, Harvard CollegePhi Beta Kappa, summa cum laude
- New York
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
April 26, 2023
BAT’s Agreement with U.S. DOJ and OFAC
On April 25, 2023, Cravath client British American Tobacco p.l.c. (“BAT”) announced it has reached agreement with the U.S. Department of Justice (“DOJ”) and U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”) to resolve previously disclosed investigations into suspicions of sanctions breaches.
Deals & Cases
September 26, 2022
Novartis Wins Dismissal of Action Alleging False Claims Acts Violations
On September 13, 2022, Judge Kimba M. Wood of the United States District Court for the Southern District of New York ruled in favor of Cravath client Novartis, dismissing with prejudice a third amended complaint filed by Relator Steven M. Camburn. In the complaint, Relator asserted claims under the False Claims Act and analogous state laws based on Novartis’s promotion of the multiple sclerosis drug Gilenya.
Deals & Cases
September 01, 2022
Novartis Directors and Officers Win Dismissal of Shareholder Derivative Suit in New York Supreme Court
On August 19, 2022, the New York Supreme Court Commercial Division issued a decision dismissing a shareholder derivative action filed against current and former directors and officers of Novartis AG (“Novartis”) and several Novartis subsidiaries who, along with the Company, were represented by Cravath. Justice Margaret Chan of the Commercial Division dismissed the suit without prejudice to refile in Basel, Switzerland as required by a forum selection clause contained in Novartis’s Articles of Incorporation.
Deals & Cases
May 02, 2022
Texas Court of Criminal Appeals Stays Execution of Death Row Inmate and Remands Habeas Claims to Trial Court
On April 19, 2022, Cravath, working on a pro bono basis, submitted an amicus brief on behalf of the Innocence Network in support of death row inmate Melissa Lucio’s application for habeas corpus and motion to stay execution. Just two days before the scheduled execution, on April 25, 2022, the Texas Court of Criminal Appeals issued a per curiam opinion staying the execution and remanding the habeas claims to the trial court for a merits review.
